| 2002 | Observation of Cabibbo-suppressed and W-exchange Λc+ baryon decays | PHYSICS LETTERS B |
| 2010 | Outcome of adjuvant therapy for gallbladder cancer | ONCOLOGY |
| 1996 | Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain | ONCOLOGY |
| 2016 | Overexpression of Endoplasmic Reticulum Oxidoreductin 1-α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer
| CANCER RESEARCH AND TREATMENT |
| 2013 | Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2012 | Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2009 | Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. | CHEMOTHERAPY |
| 2003 | Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non-Small Cell Lung Cancer
| CANCER RESEARCH AND TREATMENT |
| 2016 | Phase II trial of dacomitinib in patients with HER2-positive gastric cancer | GASTRIC CANCER |
| 2008 | Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. | ANTI-CANCER DRUGS |
| 2006 | Preoperative staging accuracy of multidetector row computed tomography for extrahepatic bile duct carcinoma | JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY |
| 2017 | Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
| JOURNAL OF GASTRIC CANCER |
| 2011 | Prognostic factors of second and third line chemotherapy using 5-fu with platinum, irinotecan, and taxane for advanced gastric cancer.
| CANCER RESEARCH AND TREATMENT |
| 2017 | Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score | JAMA ONCOLOGY |
| 2014 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | LANCET |
| 2015 | Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 1997 | Relationship between p53 Overexpression and Gastric Cancer Progression | ONCOLOGY |
| 1997 | Retrospective Comparison of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Modified FAM) Combination Chemotherapy Versus Palliative Therapy in Treatment of Advanced Gastric Cancer | American Journal of Clinical Oncology |
| 2008 | Salvage chemotherapy with docetaxel and epirubicin for Advanced/Metastatic gastric cancer | ONCOLOGY |
| 2018 | Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY |
| 2016 | Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2017 | Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2014 | Targeted therapy in gastric cancer: Personalizing cancer treatment based on patient genome
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2012 | Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2012 | Treatment outcome of patients with anaplastic thyroid cancer: a single center experience
| YONSEI MEDICAL JOURNAL |
| 2005 | 간세포암 환자에서 간동맥 화학색전술 후 발생한 급성 간부전의 위험인자
| Korean Journal of Medicine (대한내과학회지) |
| 1996 | 골육종환자에서 다방면 복합요법의 효과 및 P-Glycoprotein 과다발현의 임상적 의의
| Journal of the Korean Cancer Association(대한암학회지) |
| 1995 | 근치적 절제술이 시행된 대장 및 직장암에서 c-erbB-2의 표현과 임상적 의의
| Journal of the Korean Cancer Association(대한암학회지) |
| 1999 | 노령층 비호지킨 림프종 환자의 치료성적 및 예후
| Journal of the Korean Cancer Association (대한암학회지) |
| 2012 | 복강 내에서 발견된 기관지원성낭종 내의 선암 1예
| Korean Journal of Medicine |
| 1997 | 생물학적 치료 목표로서 위암에서 Midkine 발현의 탐색 | Journal of the Korean Cancer Association (대한암학회지) |
| 2013 | 성인에서 천미부 기형종의 선암으로 전환 1예
| Korean Journal of Medicine |
| 1996 | 악성 종양 환자에서 새로운 Anthracycline 유도체: DA-125의 제1상 및 약동학 연구
| Journal of the Korean Cancer Association(대한암학회지) |
| 1996 | 위암에서 침윤과 전이의 새로운 생물학적 표지자로서 urokinase-type plasminogen activator(uPA)의 발현
| Journal of the Korean Cancer Association(대한암학회지) |
| 1995 | 위암환자의 종양지표지자로서 혈액내 c-erbB-2 종양단백의 탐색
| Journal of the Korean Cancer Association(대한암학회지) |
| 1995 | 인체 위암조직에서 새로운 생물학적 치료목표로서 기저막 단백분해효소(Matrix-metalloproteinase-2,-9)의 발현
| Journal of the Korean Cancer Association(대한암학회지) |
| 2006 | 임신 중 발견된 뇌전이를 동반한 유방의 원발성악성림프종 1예
| Korean Journal of Hematology |
| 1995 | 임파절 전이가 없는 유방암의 예후인자
| Journal of the Korean Cancer Association(대한암학회지) |
| 1996 | 직장암에서 c-erbB-3의 발현과 예후인자로서 임상적 응용
| Journal of the Korean Cancer Association(대한암학회지) |
| 1995 | 진행위암환자에서 지속주입 5-Fluorouracil,Doxorubicin,Mitomycin-C(Modified FAM) 병용요법과 보조요법의 후향적 비교연구
| Journal of the Korean Cancer Association(대한암학회지) |
| 1995 | 항암화학요법에 의하여 골수억제가 수반된 진행암 환자에서 Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor(rhGM-CSF,LBD-005)의 제3상 임상연구;rhGM-CSF의 백혈구 감소증에 대한 효과
| Journal of the Korean Cancer Association(대한암학회지) |
| 2015 | 혈액투석 환자에서 발생한 카포시육종의 Pazopanib 치료 증례
| Korean Journal of Medicine |
